Latest news with #Glyph
India Today
21-05-2025
- India Today
Nothing Phone (3) gets a launch schedule: Key specs, features and possible India price
After months of anticipation and several mid-range launches, Nothing has finally announced the official launch timeline for its next flagship — the Nothing Phone (3). The flagship from the company is launching in India in July 2025. The device will mark Nothing's return to the premium smartphone segment, almost two years after the launch of the Nothing Phone (2), which was launched on July 11, the exact launch date hasn't been disclosed yet, the announcement confirms what Nothing CEO Carl Pei teased during a recent AMA session on social media. He hinted that the flagship would arrive in Q3 of 2025 and even mentioned a possible price range. At present, Nothing has not revealed much about the specifications or what to expect. However, it is likely to follow its usual approach of gradually revealing features in the lead-up to the launch, something that has helped it maintain buzz in the to expect from the Nothing Phone (3)Although Nothing has kept most official details under wraps, Carl Pei has confirmed that the Phone (3) will bring major upgrades in performance, improved materials, and significant software enhancements compared to its predecessor. On the design front, the phone is expected to retain Nothing's signature transparent rear panel. However, we may see enhancements in the Glyph lighting system, offering users more customisation options and new interactive features with the Phone (3). There are also reports about a new Dot Matrix Glyph on the back which may display more advanced visual cues for notifications and real-time is also focusing heavily on AI, and the Nothing Phone (3) is expected to be the first flagship from the brand to integrate AI-driven features deeply into its user experience. Pei has previously discussed the role of AI in creating more personalised and intuitive smartphone year's budget Phone (3a) series and even the sub-brand CMF Phone (2) Pro include AI features like the TrueLens Engine 3 (an AI-powered camera system) and the Essential Key. So, we can expect Nothing to bring in these AI experiences with its true flagship and some more. The Phone (3) might also include features like context-aware UI suggestions, smarter voice commands, camera enhancements, and machine learning-powered battery Phone (3) chipset and performance upgradesUnder the hood, the Phone (3) is expected to be powered by a flagship chipset from Qualcomm Snapdragon. While the exact model hasn't been confirmed, rumours suggest it could be either the Snapdragon 8s Gen 4 or the Snapdragon 8 Gen 4. Given that the new flagship is arriving almost two years after its predecessor, the chipset upgrade is likely to represent a significant leap from the Snapdragon 8+ Gen 1 that powered the Phone (2), promising improved multitasking, gaming performance, and energy Phone (3) rumours: Display and batteryadvertisementOn the front, leaks suggest that the Phone (3) could sport a 6.77-inch 1.5K LTPO AMOLED display with a 120Hz adaptive refresh rate and peak brightness of up to 3,000 nits. The phone is also expected to house a 5,000mAh battery, with support for 50W wired and 20W wireless charging. There is no confirmation yet on whether a charger will be bundled in the box, although Nothing might include it for its Indian Phone (3) to get a powerful camera setup?This year, the budget phones from Nothing received serious camera hardware upgrades. So, for the flagship, we're expecting nothing but the best from the brand. According to leaks, the Phone (3) might feature a triple rear camera setup, including a high-resolution main sensor, an ultra-wide lens, and, for the first time, a periscope-style telephoto camera—a first for any Nothing device. On the front, the phone may offer either a 32-megapixel or a 50-megapixel Sony Phone (3) expected pricing in IndiaCarl Pei has hinted that the Phone (3) could be priced around EUR 800 globally, which roughly translates to Rs 90,500. However, Nothing is likely to adopt a more competitive pricing strategy in India, as it has done in the past. The Phone (2) launched at Rs 44,999, and while a sharp price jump is expected for the Phone (3), it's unlikely to be speculation suggests the device could be priced between Rs 55,000 and Rs 65,000 for the base variant. This price tag would put Phone 3 in direct competition with other flagships like the Pixel 9a, iPhone 16e, and the OnePlus 13.
Yahoo
31-03-2025
- Business
- Yahoo
Seaport Therapeutics to Participate in Upcoming Investor Conferences in April
BOSTON, March 31, 2025--(BUSINESS WIRE)--Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that members of its management team will participate in the following upcoming investor conferences: 24th Annual Needham Healthcare Conference The Seaport management team was invited to present on Monday, April 7th at 3:45pm EDT. The live and archived webcast will be available under the Events section of the Company's website at Management will also participate in one-on-one meetings at the conference. Citi Biotech Private Access Day The Seaport management team was invited to participate in one-on-one meetings at the virtual conference on April 24th. About Seaport Therapeutics Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph™ technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and is guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit View source version on Contacts Public Relationspublicrelations@ Investor Relationsir@
Express Tribune
04-03-2025
- Business
- Express Tribune
Nothing takes on Apple and Samsung with stylish budget phone series
British startup Nothing has launched its latest Phone (3a) Series, aiming to disrupt the mobile industry's stagnation with bold design choices and high-end features at a competitive price. PHOTO: ZDNET Listen to article British startup Nothing has launched its latest Phone (3a) Series, aiming to disrupt the mobile industry's stagnation with bold design choices and high-end features at a competitive price. The Phone (3a), starting at £329 ($414), introduces a unique design with distinctive shapes and Glyph lights on the back for customizable notifications. The higher-end Phone (3a) Pro, priced at £449, enhances the camera experience with a 50MP triple-lens setup and optical image stabilization. Both devices run on Qualcomm's Snapdragon 7s Gen 3 processor, a shift from the MediaTek chipset used in the previous generation. CEO Carl Pei, co-founder of OnePlus, envisions Nothing as an alternative to the "sea of smartphone sameness". The brand has grown rapidly, with 557% year-over-year growth in India in 2024. However, the Phone (3a) Pro will not be available in India, as the company focuses on price-sensitive markets. Despite its premium design and gaming enhancements like a 4,500 mm² vapor chamber for cooling and RAM Booster for up to 20GB memory, analysts suggest that Nothing will need to be extremely price-competitive to succeed against giants like Apple and Samsung. With over 7 million units sold across its product lineup and $1 billion in revenue, Nothing is betting big on its latest launch, hoping to carve out a niche in an increasingly saturated market.
Yahoo
04-03-2025
- Yahoo
Nothing's Phone 3a Pro is a stylish, almost-flagship experience for $459
Nothing doesn't have a Phone 3 yet, instead choosing to make a lateral move to not one, but two new mid-range devices, the Nothing Phone 3a and, intriguingly, the 3a Pro. Reassuringly, Nothing continues to design phones unlike anything else out there. Its retro-future design aesthetic for the exposed-but-not hardware on the rear of the phones, as well as the dot-matrix fonts, animations and software, are all back. Hardware design remains Nothing's biggest strength. I get asked about the Nothing phone more than I do when I'm using the latest iPhone, Samsung's foldables or anything else. It's just different. The Phone 3a series now has a glass backing (upgraded from polycarbonate) and you can still see screw fittings, electronics and a return of Nothing's Glyph lighting system. The Phone 3a is rated IP64, adding better protection this year against rogue water sprays and liquid incidents. Nothing Phone 3a and 3a Pro hands-on Nothing has once again rejigged the exposed hardware, and the Glyph lighting details are all at the top of the phone, circling the camera unit. On the Phone 3a Pro, courtesy of a new periscope sensor capable of 3X optical zoom, a substantial circular camera unit protrudes from the back. Advertisement If you think the 3a Pro's camera module looks chunky, it also adds roughly 10 grams to its weight compared to the base Nothing Phone 3a. But for camera obsessives, only one of these phones will hold your attention. (Although the blue iteration of the Nothing Phone 3a is gorgeous.) The Nothing Phone 3a Pro's 50-megapixel telephoto sensor can stretch to 3x optical zoom, but it also includes a rather useable, in my early testing, lossless cropped 6x zoom. There's also a 50MP primary sensor with f/1.88 lens, and dual-pixel phase detection auto-focus (PDAF). Nothing has crammed in an ultrawide 8MP sensor with a 120-degree field of view. The 3a Pro also has a telemacro mode and can combine focus as close as 15cm (5.9 inches) away with the zoom of the telephoto. It's a feature that makes macro photography far more useful – and still rare on phones outside of China. The base model Phone 3a's main 50MP camera has single-pixel PDAF, but otherwise keeps the same primary camera specs. Its telephoto stretches to 2x optical zoom, and a third ultrawide 8MP camera. Advertisement While we'll explore the camera more deeply in our review, my early impressions are positive. Images are crisp and Nothing has a knack for curated filters that look good. I especially like the frosted glass effect, which Nothing also offers for wallpaper customization. Nothing Phone 3a and 3a Pro hands-on Nothing says its TrueLens Engine 3.0 combines AI-powered tone mapping with Ultra XDR, which it co-developed with Google, to tune photos. It involves a burst of 8 RAW images, which are all processed together to adjust the brightness of each pixel up to five times. Nothing's image processing seems to lean towards punchy, high-contrast photos and video. The Phone 3a and Phone 3a Pro are otherwise identical in specs. Compared to the Nothing Phone 2a, both new devices have a bigger 6.77-inch AMOLED LTPS display, now using Panda Glass rather than Corning's Gorilla Glass. As you might expect from most (but not all) phones, the 3a has an always-on display, can reach 120Hz refresh rates and it now hits 1,300 nits, making it brighter than the company's last phone, too. Once again, the phones both have a big 5,000mAh battery and fast charging at up to 50W. According to Nothing, this means it should take less than an hour to charge the device entirely, while you should be able to get halfway there in 19 minutes. One of the only parts of the Nothing Phone 3a series that hints that they aren't quite at a flagship level is their processor: a Snapdragon 7s Gen 3. We'll put that chip through its paces in our review, but it is supposed to help with Nothing's own custom software pecadillos, like the TrueLens Engine. The company says that chip makes the 3a series 92 percent better at AI processing than its predecessor. Advertisement In a nod to both its OnePlus history and the recent trend for adding buttons, Nothing added its Essential Key to the Phone 3a, on the right edge below the power button. Oddly, it has a different finish to the rest of the machined buttons on the 3a and feels a bit cheaper. It works like an AI assistant launcher on other smartphones, like Samsung's Gemini AI launcher, although the AI hooks come later. One press will capture and send content a screenshot to Nothing's Essential Space app, while a longer press will start recording a voice note. You can also double-press to launch straight into the Essential Space app, which is a storage space for all those collections. Nothing Phone 3a and 3a Pro hands-on Nothing uses the same AI tricks we've seen elsewhere; it just simplifies them. The Phone 3a will transcribe your voice notes, automate reminders, and even describe your photos and screenshots if needed. As I juggle work commitments, other writing projects, life and everything else, this is an intriguing soup of AI tools, storage and automation, all in a single place. This also seems to be Nothing's equivalent of Android's Labs setting. The company is teasing further functionality, such as focused search, flip-to-record, Camera Capture (using the Essential key while in the camera app), Smart Collections of all your notes and more. It seems to be the Notes equivalent of how Google Photos gives you quick and easy access to the images and videos you're looking for. With the Phone 3a Pro's software more broadly, Nothing OS is fun. Despite a learning curve in places, it's playful. The icons, fonts, and animations across Nothing's take on Android 15 add a refreshing touch of personality in a sea of smartphone sameness. Advertisement Perhaps there are a few too many creative cooks, as Nothing's decorative touches jostle with what I assume are Google's baked-in fonts and menus. Some of the icons are hard to discern, too. After powering up the Phone 3a for the first time, a pixelated smiley face appeared on the home screen. I'd tap it and realize it does nothing. It turns out this is Nothing's attempt at showing your screen time – but it doesn't need to be a 2x2 widget. Nothing Phone 3a and 3a Pro hands-on Advertisement Other nice touches include a monochrome theme (on these monochrome phones), app label removal and a smart app drawer that corrals similar apps together for more straightforward navigation. Availability in the US will come through a Beta Program, like in previous years. The Phone 3a ($379) is available to preorder now in grey, black and blue, with devices landing March 11, while the Phone 3a Pro ($459) in black and grey, goes on preorder March 11 and launches March 25. In the UK, the company's Nothing Store in London will be one of the first places to offer the phone directly, from 11AM GMT on March 8.
Associated Press
12-02-2025
- Business
- Associated Press
PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ('Seaport') a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the publication of new data showcasing the Glyph TM platform's unique ability to enhance drug transport through the lymphatic system for increased therapeutic exposure. The paper, published in Molecular Pharmaceutics, is the first to show the impact of changing the drug attachment point of a lymph-directed prodrug on lymphatic drug transport and targeted drug exposure. It also deepens the evidence supporting Glyph's ability to render a wide variety of molecules, including immunomodulators, more amenable to lymphatic transport and thus providing them with direct access to the immune system. The full text of the announcement from Seaport is as follows: Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with Glyph TM Platform Published data shows new site of Glyph prodrug attachment demonstrated highest reported level of lymphatic transport to date of the studied immunomodulatory drug New linkers display up to two-fold higher release in lymph nodes compared to top-performing previously reported linkers Research builds on prior evidence supporting the versatility of Glyph platform BOSTON, February 12, 2025 – Seaport Therapeutics ('Seaport' or the 'Company'), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the publication of new data showcasing the Glyph TM platform's unique ability to enhance drug transport through the lymphatic system for increased therapeutic exposure. The paper, published in Molecular Pharmaceutics, is the first to show the impact of changing the drug attachment point of a lymph-directed prodrug on lymphatic drug transport and targeted drug exposure. It also deepens the evidence supporting Glyph's ability to render a wide variety of molecules, including immunomodulators, more amenable to lymphatic transport and thus providing them with direct access to the immune system. The study evaluated ways of modifying mycophenolic acid (MPA), an immunomodulatory drug, to improve its absorption through the lymphatic system, and increase its concentration in lymph nodes, shown in preclinical models. Specifically, a comparison between distinct attachment points on the same drug molecule was made. A newly examined phenol attachment point showed the highest lymphatic transport of MPA reported to date – approximately 55 percent – and up to two-fold higher release in lymph nodes compared to the previously reported acid attachment point. The research demonstrated the impact of linker characteristics on the extent of lymphatic transport and release in the lymph nodes. Overall, these results help to underscore the benefits of a tailored lymphatic-targeting prodrug design approach. 'This research expands our understanding of lymphatic delivery and offers new insights for more effectively designing drugs with higher exposures at their intended targets, including immunomodulatory drugs used to treat a wide range of diseases,' said Christopher Porter, Ph.D., an original Co-inventor of the Glyph technology and Director of the Monash Institute of Pharmaceutical Sciences at Monash University in Melbourne. 'This study highlights the importance of integrating a careful and individualized balance of intestinal stability, transport efficiency and release in the mesenteric lymph nodes to maximize therapeutic exposures as part of a tailored prodrug design approach.' With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group, including co-inventors Professor Porter and Jamie Simpson, Ph.D., who is now Head of Chemistry at Seaport Therapeutics. 'Our Glyph platform allows for a bespoke design approach, and this research reinforces the significance of the innovation behind our prodrug chemistry technology,' said Daniel Bonner, Ph.D., Co-founder, Senior Vice President, Platform, at Seaport Therapeutics. 'Most importantly, Glyph has been clinically validated with demonstrated proof-of-concept data in humans and is being applied across Seaport's pipeline of novel neuropsychiatric medicines, with enormous potential across a broad range of applications beyond CNS and neuropsychiatry.' About the Glyph TM Platform Glyph TM is Seaport's proprietary technology platform which uses the lymphatic system to enable and enhance the oral administration of drugs. With the Glyph platform, drugs are absorbed like dietary fats through the intestinal lymphatic system and transported into circulation. The Glyph platform has the potential to be widely applied to many therapeutic molecules that have high first-pass metabolism leading to low bioavailability and/or side effects, including liver enzyme elevations or hepatotoxicity. Seaport exclusively licensed this technology from Monash University based on the pioneering research of the Porter Research Group. Advanced initially at PureTech Health and now at Seaport, Glyph has been applied to create therapeutic candidates for the Company's pipeline resulting in new intellectual property, including composition of matter. The group and its collaborators have published research in Nature Metabolism, Frontiers in Pharmacology, Journal of Controlled Release and Molecular Pharmaceutics supporting the Glyph platform's capabilities. See Glyph in action here. About Seaport Therapeutics Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. The Company has a proven strategy of advancing clinically validated mechanisms previously held back by limitations that are overcome with its proprietary Glyph TM technology platform. All the therapeutic candidates in its pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce liver enzyme elevations or hepatotoxicity and other side effects. Seaport is led by an experienced team that invented and advanced important neuropsychiatric medicines and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders. For more information, please visit About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to Seaport's development plans for its pipeline of neuropsychiatric therapeutics based on the Glyph Platform, the applicability of the platform beyond neuropsychiatry, potential benefits to patients, and Seaport's and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption 'Risk Factors' in our Annual Report on Form 20-F for the year ended December 31, 2023, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. [email protected] [email protected] /EU Media Ben Atwell, Rob Winder +44 (0) 20 3727 1000 [email protected] Media Justin Chen +1 609 578 7230 [email protected] KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS SOURCE: PureTech Health plc Copyright Business Wire 2025. PUB: 02/12/2025 07:05 AM/DISC: 02/12/2025 07:05 AM
